AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
29 August 2022 - 9:00PM
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage
biopharmaceutical company focused on developing treatments for
rare, chronic, and serious infectious diseases with high unmet
needs, today announced that Eric Easom, President and CEO will
present at the H.C. Wainwright 24th Annual Global Investment
Conference
Details of the event is as follows:
H.C. Wainwright 24th Annual Global Investment Conference,
September 12-14, 2022
- An on-demand presentation from Eric Easom, President and CEO
will be available beginning Monday, September 12, 2022 at 7:00 A.M.
E.T.
A webcast of the presentation can be accessed on the Investors
section of the AN2 Therapeutics website at www.an2therapeutics.com.
An archived replay will be available for at least 30 days following
the presentation.
About AN2 Therapeutics, Inc. AN2 Therapeutics,
Inc. is a clinical-stage biopharmaceutical company developing
treatments for rare, chronic, and serious infectious diseases with
high unmet needs. AN2 is developing epetraborole, a once-daily,
oral treatment with a novel mechanism of action for patients with
NTM lung disease, a rare, chronic, and progressive infectious
disease caused by bacteria, known as mycobacteria, that leads to
irreversible lung damage and can be fatal. For more information,
please visit our website at www.an2therapeutics.com.
COMPANY CONTACT:Lucy O. DayChief Financial
Officerl.day@an2therapeutics.com
INVESTOR AND MEDIA CONTACT: Anne
Bowdidge ir@an2therapeutics.com
AN2 Therapeutics (NASDAQ:ANTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
AN2 Therapeutics (NASDAQ:ANTX)
Historical Stock Chart
From Apr 2023 to Apr 2024